CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity

Authors

  • Shengyong Yin,

    1. Department of General Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People's Republic of China
    Search for more papers by this author
    • The first two authors contributed equally to this work.

  • Jinjun Li,

    1. State Key Laboratory of Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China
    Search for more papers by this author
    • The first two authors contributed equally to this work.

  • Chen Hu,

    1. Department of General Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People's Republic of China
    Search for more papers by this author
  • Xinhua Chen,

    1. Department of General Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People's Republic of China
    Search for more papers by this author
  • Ming Yao,

    1. Experimental Pathological Laboratory, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China
    Search for more papers by this author
  • Mingxia Yan,

    1. Experimental Pathological Laboratory, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China
    Search for more papers by this author
  • Guoping Jiang,

    1. Department of General Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People's Republic of China
    Search for more papers by this author
  • Chao Ge,

    1. State Key Laboratory of Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China
    Search for more papers by this author
  • Haiyang Xie,

    1. Department of General Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People's Republic of China
    Search for more papers by this author
  • Dafang Wan,

    1. State Key Laboratory of Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China
    Search for more papers by this author
  • Shengli Yang,

    1. State Key Laboratory of Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China
    2. Shanghai Research Center of Biotechnology, Chinese Academy of Sciences, Shanghai 200233, People's Republic of China
    Search for more papers by this author
  • Shusen Zheng,

    Corresponding author
    1. Department of General Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People's Republic of China
    • State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute and Cancer Institute of Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai 200032, People's Republic of China. or Department of General Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, People's Republic of China
    Search for more papers by this author
  • Jianren Gu

    Corresponding author
    1. State Key Laboratory of Oncogenes and Related Genes, Cancer Institute of Shanghai Jiao Tong University, Shanghai 200032, People's Republic of China
    • State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute and Cancer Institute of Shanghai Jiao Tong University, 25/Ln 2200 Xietu Road, Shanghai 200032, People's Republic of China. or Department of General Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, People's Republic of China
    Search for more papers by this author
    • Fax: +86-21-64177401.


Abstract

Recently increasing reported data have suggested that only a small subset of cancer cells possess capability to initiate malignancies including leukemia and solid tumors, which was based on investigation in these cells displaying a distinct surface marker pattern within the primary cancers. CD133 is a putative hematopoietic and neuronal stem-cell marker, which was also considered as a tumorigenic marker in brain and prostate cancer. We hypothesized that CD133 was a marker closely correlated with tumorigenicity, since it was reported that CD133 expressed in human fetal liver and repairing liver tissues, which tightly associated with hepatocarcinogenesis. Our findings showed that a small population of CD133 positive cells indeed exists in human hepatocellular carcinoma (HCC) cell lines and primary HCC tissues. From SMMC-7721 cell line, CD133+ cells isolated by MACS manifested high tumorigenecity and clonogenicity as compared with CD133 HCC cells. The implication that CD133 might be one of the markers for HCC cancer stem-like cells needed further investigation. © 2006 Wiley-Liss, Inc.

Ancillary